Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

[accordions]
[accordion title= “Chemical Properties“]

[/accordion]

[accordions]
[accordion title= “References and Literature“]

1. Frieder J, et al.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.Ther Adv Chronic Dis. 2018 Jan;9(1):5-21.

[/accordion]